CDT Equity Inc.
CDT Equity Inc. (CDT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Senior Secured Convertible Promissory Note to J.J. Astor & Co. On September 14, 2026, CDT Equity Inc. (the “Company”) issued a senior secured convertible promissory note (the “Note”) to J.J. Astor & Co. (the “Lender”), in the
CDT Equity Inc. (CDT) fell 37% to $0.3783 on Thursday, despite announcing Sarborg's drug discovery advancements. CDT owns 22.7% of Sarborg, valued at $709M. Trading volume surged to 34.03M shares. CDT's 52-week range is $0.3641 to $2,360.00.
CDT Equity Inc. (CDT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Amended Securities Purchase Agreement with Sarborg Limited On August 31, 2026, CDT Equity Inc. (the “Company”) entered into an amendment (the “Amendment”) to the Securities Purchase Agreement, dated February 19, 2026 (as amend
Over the past 7 days, AlphAI's AI scored 1 news story mentioning CDT (CDT Equity Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent CDT coverage spans corporate actions, market movers and insider activity.
In the last 30 days, CDT insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale. The most active reporter was Regan Andrew, Chief Executive Officer, with 1 filing.
The new convertible note creates a senior secured debt obligation and potential dilution if converted, likely pressuring the stock short‑term.
Significant intraday price drop reflects market reaction to the update, but no material new financial data disclosed.
The financing adds cash but dilutes existing shareholders; short‑term price may react to the cash infusion and note repayment.
Minor insider sell by the CEO; unlikely to move price materially.
New leadership may signal strategic shift; short‑term price pressure observed.
AlphAI scores every news story that mentions CDT with an AI model for sentiment and relevance, and aggregates insider trades from CDT Equity Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
CDT Equity Inc. (CDT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Senior Secured Convertible Promissory Note to J.J. Astor & Co. On September 14, 2026, CDT Equity Inc. (the “Company”) issued a senior secured convertible promissory note (the “Note”) to J.J. Astor & Co. (the “Lender”), in the
1 min readCDT Equity Inc. (CDT) fell 37% to $0.3783 on Thursday, despite announcing Sarborg's drug discovery advancements. CDT owns 22.7% of Sarborg, valued at $709M. Trading volume surged to 34.03M shares. CDT's 52-week range is $0.3641 to $2,360.00.
1 min readCDT Equity Inc. (CDT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Amended Securities Purchase Agreement with Sarborg Limited On August 31, 2026, CDT Equity Inc. (the “Company”) entered into an amendment (the “Amendment”) to the Securities Purchase Agreement, dated February 19, 2026 (as amend
1 min readRegan Andrew (Chief Executive Officer) sold 290 indirectly-held shares of CDT Equity Inc. (CDT) on 2026-08-28.
1 min readCDT Equity Inc. (CDT) named co-founder James Bligh as CEO. Bligh has extensive experience in corporate finance and M&A. The company has recently strengthened its balance sheet and made strategic investments. CDT shares fell 4.76% in pre-market trading to $1.60, following a 0.59% decline the prior day.
1 min readCDT Equity Inc. (CDT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of James Bligh On August 31, 2026 (the “Effective Date”), CDT Equity Inc (the “Company”) appointed Mr. James Bl
2 min readCDT Equity Inc. (Nasdaq: CDT) invested in Pep'd Inc. via a SAFE note, gaining exposure to the growing US peptide market. The deal includes a $10M valuation cap, with conversion to shares upon Pep'd's equity financing. Pep'd combines telehealth, research, and peptide products, aiming to leverage AI for development. The global peptide market is projected to reach $294.6B by 2033, growing at 8.7% CAGR. CDT's CEO, Dr. Andrew Regan, is also Pep'd's sole shareholder.
2 min readCDT Equity Inc. (CDT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. As previously disclosed on June 11, 2026, CDT Equity Inc. (the “Company”), issued a senior secured convertible promissory note (the “Note”) to J.J. Astor & Co. (the “Lender”), in the principal amount of $1,971,000 (the “Princi
6 min readCDT Equity Inc. (CDT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Transactions with Investors of Sarborg Limited On July 30, 2026, CDT Equity Inc., a Delaware corporation (the “ Company ”), entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain stockholders (c
4 min readCDT Equity Inc. (CDT) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities. On July 24, 2026, CDT Equity, Inc. (the “Company”) issued 32,110 shares of common stock, par value $0.0001 per share (the “Common Stock”) at a value of $3.27 per share to a service provider as consideration for certain consulting
2 min read